Browse by:
Technology

Framingham firm receives N.Y. certification

Framingham-based Boston Heart Diagnostics Corp. announced it can now serve patients with its diagnostics into personalized nutrition and lifestyle programs for patients with or at risk...

Report: VCs invest more for software, less for life sciences

The software industry in the United States drew $4 billion in venture capital during the first quarter of this year, its highest level in 14 years, according to a report from...

Stratus taps Colo. firm to boost resell

John Agoglia |

Maynard-based software provider Stratus Technologies, Inc., is partnering with Arrow Electronics of Englewood, Colo., to expand its reach through Arrow's network of authorized resellers.

BSX wins FDA approval on heart devices

Natick-based Boston Scientific Corp. (BSX) has received approval for its newest defibrillators and heart failure devices, including the trademarked Dynagen Mini, Inogen Mini ICDs, and the Dynagen XF...

Natick company receives $3M order

Emily Micucci |

Natick-based Cognex Corp., which manufacturers machine sensors, said it received more than $3 million in purchase orders for its DataMan barcode readers.

Sepaton awarded data deduplication patent

Michael Novinson |

Marlborough-based Sepaton has been awarded a patent for a process that improves deduplication ratios and speed, the company announced Tuesday.

Bose sues over alleged patent infringement

Michael Novinson |

Bose Corp. filed a lawsuit last week against Monster Inc., accusing the California-based rival of infringing on the Framingham-based audio technology company's design for in-ear headphones.

Stratus parent credit rating improves

Michael Novinson |

The credit rating for the parent company of Stratus Technologies has improved after the Maynard-based company announced it was being sold to a private equity firm.

Karyopharm finds clinical partner, possible new uses for cancer drug

Emily Micucci |

Karyopharm Therapeutics of Natick has produced promising results as it develops its cancer drug, KPT-330. Now, the startup is exploring other potential applications for its technology.

Mass. life sciences firms look beyond VCs for funding

Michael Novinson |

When Geert Cauwenbergh needed money for a life sciences startup in 2002, he knew where to turn: venture capitalists.

ADVERTISEMENTS
Copyright 2014 New England Business Media